AbCellera Biologics (ABCL) Corporate presentation summary

Company overview and platform

• Clinical-stage biotech focused on novel antibody medicines, with a fully integrated platform from discovery to clinical manufacturing and development.

• Over $1B invested in the platform, with 20+ internal program starts and 2 molecules in the clinic.

• Operates 300K+ sq ft of research and manufacturing facilities, with ~600 employees across Vancouver, Montreal, and Sydney.

• IPO completed in December 2020, with ~$655M in liquidity as of March 31, 2026.

• More than 100 partner-led programs supported, with 12 molecules in the clinic through partnerships.

Strategic focus and pipeline

• Shifted focus in 2023 from partnerships to advancing an internal pipeline.

• Strategy leverages competitive advantage in antibody drug creation to build a differentiated pipeline, including GPCR and ion channel targets, and novel modalities like multispecifics and ADCs.

• Internal pipeline includes two programs in the clinic (ABCL635, ABCL575), two in IND-enabling activities (ABCL688, ABCL386), and 20+ discovery programs.

• 2026 priorities include key data readouts for ABCL635 (Phase 2) and ABCL575 (Phase 1), and preparation for three additional INDs in 2027.

ABCL635 program highlights

• ABCL635 is a potential first-in-class antibody for non-hormonal treatment of vasomotor symptoms (VMS) in menopause, targeting NK3R (a GPCR).

• Addresses a large unmet need: ~12M US women experience moderate-to-severe VMS, with >6M seeking treatment and 20% unsuitable for hormone therapy.

• Estimated $6B+ total addressable market for non-hormonal VMS treatments.

• Phase 1 data showed favorable tolerability, no liver toxicity, and a PK profile supportive of monthly dosing.

• Phase 2 trial is enrolling, with topline results expected in Q3 2026; additional opportunities in oncology are being explored.